Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.53 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: cafusertib, onvansertib, bi-2536 +5 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 9 Parkinson's papers of 3,688 | 0.70 |
| pathways Reactome | 25 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 11468
Earlier readings: 2026-10-26 0.54; 2026-10-25 0.54; 2026-10-24 0.54; 2026-10-23 0.54.
Sealed predictions
- PLK1 in dopamine neurons, braak-0.11 (p 0.787) → -0.43 (p 0.247)receipt 0172
Swarm cases
receipt 0172: PLK1 in dopamine neurons, braak
- power
- full sample -0.24 (p 0.346, n 18), 95% CI -0.63 to +0.26. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.26 (p 0.294, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.26 (p 0.294, n 18). could be the mix.
- skeptic
- leave-one-out range -0.38 to -0.14, sign flips 0; without severely affected donors -0.24 (p 0.346, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PLK1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts